Grade III/IV CRAEs association with chemotherapy in ITT analysis
deaths
ADVERSE EFFECTS
The relative percentage of grade III/IV chemotherapy-related adverse effects (CRAEs) in ITT analysis was lower in the ChemoID assay-guided group (51%) vs. the physician-choice group (79%), with no unexpected neurological CRAEs or deaths due to CRAEs in either arm (